Lupus & antiphospholipid syndrome
Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis
Authors' conclusion
ICAM2 (CD102) may serve as a potential serum biomarker for proliferative LN that reflects renal pathology activity, potentially contributing to the progression of LN through the PI3K/Akt pathway.
Study context
- Population
- Patients with lupus nephritis (LN) and healthy controls
- Comparison
- LN vs healthy control (HC); proliferative vs non-proliferative LN
- Outcome
- Serum ICAM2 (CD102) as LN biomarker
Methodological detailsLC-MS/MS serum proteomics, machine learning selection, independent validation cohort, kidney tissue verification, in vitro siRNA knockdown
- LC-MS/MS serum proteomics
- Machine learning selection
- Independent validation cohort
- Kidney tissue verification
- In vitro siRNA knockdown
Performance
As reported in the abstract
ICAM2 highest AUC distinguishing LN from HC
AUC=0.92
Original publication
Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis. Lupus Sci Med. Published 23 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →